Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bridgepoint to Ask JPMorgan to Advise on Diaverum Future

Jan. 21 (Bloomberg) -- Bridgepoint Advisers Ltd., a U.K. private-equity firm with more than $12 billion in committed funds, will choose JPMorgan Chase & Co. to consider Swedish renal-care provider Diaverum’s future.

Bridgepoint “is close” to completing JPMorgan’s appointment to look at strategic options for Lund-based Diaverum for the next 12 months, James Murray, a spokesman for the firm, said by phone today.

Diaverum provides renal care to more than 20,000 patients at about 250 clinics in 17 countries, including in South America, Australia, Europe and the Middle East, according to information on its website. The company employs 6,900 people and reported sales of 398 million euros ($530 million) in 2011. Companies owned by London-based Bridgepoint employ 72,000 people in more than 40 countries, according to its website.

To contact the reporters on this story: Aaron Kirchfeld in London at akirchfeld@bloomberg.net; Niklas Magnusson in Stockholm at nmagnusson1@bloomberg.net

To contact the editor responsible for this story: Frank Connelly at fconnelly@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.